


PERSONAL INFORMATION

NAME: Despina Smirlis

WEBSITE: <https://www.pasteur.gr/en/molecular-parasitology-2/>

WORK ADDRESS:

Molecular Parasitology Laboratory,
Microbiology Dpt, Hellenic Pasteur Institute, 127 Bas. Sofias Ave., Zip:11521,
City: Athens, Country: Greece
E-mail: penny@pasteur.gr
Telephone: +302106478841 (stable line)



EDUCATION

Years	Degree	University
1993-1996	BSc Biochemistry, Honours, upper second class	Imperial College London, University of London
1997-2001	Ph.D. Biochemistry and Molecular Biology; Thesis: Transcriptional Regulation of Rat <i>CYP2B</i> Genes	University College London, University of London

EMPLOYMENT RECORD

POSTDOCTORAL POSITIONS

Years	Placement
1-2001/ 9-2001	Molecular Diagnostics Laboratory/ Protein Crystallography Laboratory, Biology Department, NCRS Democritus
1997-2001	Post-doctoral research training at Molecular Parasitology Lab group of Hellenic Pasteur Institute

ACADEMIC APPOINTMENTS

Years	Placement
8- 2007 / 3-2014	Researcher grade D (Research Fellow/Lecturer level) at the Molecular Parasitology Laboratory, Microbiology Department, Hellenic Pasteur
3/2014-8/2021	Researcher grade C (Junior investigator) at the Molecular Parasitology Laboratory, Microbiology Dpt Hellenic Pasteur Institute
1/2016-10/2017	Visiting Scientist at the Molecular Parasitology and Signaling Unit, Institut Pasteur
8- 2021- today	Researcher grade B (Principal investigator) at the Molecular Parasitology Laboratory, Microbiology Dpt Hellenic Pasteur Institute

Junior Investigator,

PROFESSIONAL ACTIVITIES

AWARDS-HONOURS

- Welcome Trust Toxicology Ph.D. Prize Studentship (1997-2001)
- Recipient of the Short Mission Fellowship of the COST BM0802 Action for training in the Trypanosome Cell Biology Laboratory CNRS URA 2581, Institut Pasteur Paris (09/2009)

- Greek Management Committee substitute member of the BM0802 action- Life or death of protozoan parasites (2009-2012)
- Recipient of the Programme Calmette and Yersin traineeship (International Pasteur Network) in the Molecular Parasitology and Signalling Unit of Institut Pasteur: "Generation of conditional *Leishmania* Aurora null mutants for investigating the role of this kinase in the parasitic life-cycle and evaluating its potential as a putative drug target for anti-leishmanial chemotherapy" (4-8/2013)
- Coordinator of Actions Concertées des Instituts Pasteur (ACIP, 2013) (2013-2015)
- Greek Management Committee Substitute Member for Greece in the COST CM1307 ACTION "Targeted chemotherapy towards diseases caused by endoparasites" (2015-2018)
- Recipient of the Short Mission Fellowship of the COST CM1307 Action "Investigating regulatory & functional elements of *Leishmania infantum* Aurora kinase, and assessment of its role in parasite genomic adaptation" in the Molecular Parasitology and Signalling Unit of Institut Pasteur (9-12/2015)
- Awarded Medal of honor by UNESCO-Hellas for Scientific achievement (11-02-2016)

COMMITTEE ASSIGNMENTS AND INSTITUTIONAL RESPONSIBILITIES

- Member of the Institutional Health and Security Committee (2014-2017)
- Member of different institutional committees for the procurement of consumables and instruments (2014-2022)
- Member of the Ph.D. and MSc evaluation committees, personnel recruitment committees (Technical Personnel and post-doctoral personnel), and evaluation committees for university assistant professor recruitment and promotion
- Head of the FACS Unit of the Hellenic Pasteur Institute (2007-present)
- Member of the Institutional Evaluation Committee (2021-2022)
- Member of an institutional committee for the creation of a center of excellence to enhance research, surveillance, and prevention of emerging and re-emerging infectious diseases (26,2 million euros) [EU Recovery and Resilience fund/ private investment and transformation of the economy GSRI). The committee is responsible for the recruitment of instruments (7 million).
- Expert evaluator of GSRI for grant proposals

OTHER RESPONSIBILITIES

- **Head of the National Reference Lab for Leishmaniasis** (2002) -Hellenic CDC (EODY) accredited

EDITORIAL ACTIVITIES

- Peer review of scientific journals (PLOS Pathogens, PLOS One, International Journal of Parasitology, Parasitology, Parasites & Vectors, Mini-Reviews in Medicinal Chemistry, Asia Pacific Journal of Mol. Biology and Biotechnology Proteomics, Biomedicines, Molecules, and others)
- Guest Editor in Biomedicines (IF:6082), MDPI. Special Issue "Recent Advances in Treatment and Diagnosis of Leishmaniasis, Trypanosomiasis and Other Neglected Tropical Diseases"

TEACHING EXPERIENCE

1997-2000	Demonstrator at the UCL undergraduate Molecular Biology Course B200
1998-1999	Demonstrator and tutor at Molecular Biology Practicals of the MSc course: Applied Molecular Biology and Biochemistry
12/2012	Lecturer at the Research seminar of the Biology Department of the National Kapodistrian University of Athens: The unusual lives of trypanosomatids
11/2016	Institut Pasteur, Tehran, Iran: International Workshop " <i>Leishmania</i> and leishmaniasis immunology, vaccine and drug discovery-therapy" Speaker: Recent approaches in anti-leishmanial drug discovery

FINAL YEAR THESES /INTERNSHIPS

2007-2008	Final year project supervisor of Anastasios Katopodis, thesis "Cloning and molecular characterization of the <i>Leishmania</i> protein Ran", National and Kapodistrian University of Athens
2008	Final year project supervisor of Irene Daoudadakis, thesis "Construction of targeted cassettes for the knockout of <i>Leishmania</i> protein Ran", Technical University of Athens
2009	Final year project Supervisor of Evangelos Nomikos, thesis "Expression and purification of a <i>Leishmania</i> RCC1 protein fragment", Technical University of Athens
2015-2016	Final year project supervisor of Garyfallia Loulou, thesis in the Final Year Project "Phenotypic characterization of <i>Leishmania infantum</i> parasites knocked out or over-expressing the <i>Leishmania</i> dual-specificity tyrosine regulated kinase 1 (DYRK1), for the study of its biological role"
2015-2016	Final Year Project Supervisor: Foteini Kolokousi, thesis "Investigating the role of <i>LinDYRK1</i> in <i>Leishmania Infantum</i> ", National and Kapodistrian University of Athens, (Thesis granted in 2017)
2019	Final Year Project Student Supervisor: Georgios Siotas, thesis "Production and purification of <i>Leishmania</i> kinases for the development of kinase assays", University of West Attica
04-09 2019	Group leader in charge of Daniel Carrasco Navarro: Exchange postgraduate student, Erasmus for Young Entrepreneurs
7/2020-9/2020	Internship supervisor of Emilia Damaskou, University of Crete
7/2020-9/2020	Internship supervisor of Alexandros Balaouras, Agricultural University of Athens
9/2020-2021	Final Year Project supervisor of Alexandros Balaouras, Agricultural University of Athens (thesis pending)
2021	Supervisor of internship student Olga Angeli (Democritus University of Thrace)
2021	Supervisor of Internship student Nefeli Kontouli (Democritus University of Thrace)
2021-2022	Internship supervisor of Christina Leskou (University of West Attica)
2021-current	Final year project supervisor of Nefeli Kontouli, thesis "Drugs and drug targets for the treatment of leishmaniasis", (Democritus University of Thrace)
2022-current	Final year project supervisor of George Karanikas "Characterisation at the molecular level of <i>Leishmania</i> parasite drug resistance" (University of West Attica)
2022-current	Final year project supervisor of Andriani Lagounari (University of West Attica) In vivo efficacy or resistance of antileishmanial drugs against <i>L. donovani</i> complex parasites
2022-current	Supervisor of internship student Tina Soulti (University of West Attica)

MSc THESES/Ph.D. THESES

2010-2013	Co-supervisor of Alexandros Alexandratos, Ph.D. thesis "Study of molecules important for cell-cycle progression in the protozoan parasite <i>Leishmania</i> ", University of Ioannina
2010-2014:	Co-supervisor of Antonia Efstathiou, Ph.D. thesis "Study of molecules implicated in the development of <i>Leishmania</i> and <i>T. brucei</i> parasites", National and Kapodistrian University of Athens
2013-2017	Co-supervisor with Dr Milena Soares (FIOCRUZ, Bahia, Brazil) of Vinicius Pinto Rocha, Ph.D. thesis " <i>Leishmania infantum</i> Dyrk1 in the development of infective promastigotes and in stage differentiation", FIOCRUZ
2017-2018	Supervisor of Dedousis Glymis. MSc thesis "Investigation of the role of Aurora kinase of the parasite <i>Leishmania</i> via the use of transgenic mutants", National and Kapodistrian University of Athens
2021-current	Supervisor of Daniel Carrasco Navarro, Ph.D. Thesis "Phospho-signalling at the host-pathogen interface: the role of DYRKs and other kinases in <i>Leishmania</i> infections, University of Alcalá, Madrid, Spain
2022-current	Supervisor of Konstantinos Pitsias, MSc thesis "Study of macrophage molecular targets for the treatment of leishmaniasis"
2022- current	Supervisor of Stavroula Kroustalli, MSc thesis "Overview of the antileishmanial action of natural products"

INVITED LECTURES -CONFERENCES (ORGANISATION/INVITATIONS)

1. Research seminar of the Biology Department of the National Kapodistrian University of Athens: The unusual lives of trypanosomatids, 19-12-2012
2. UMR8638 CNRS-Université Paris Descartes, "Novel drug targets and drugs for the treatment of leishmaniasis", 19-7-2013
3. Institute Pasteur Paris, Scientific Symposium of the Institut Pasteur International Network "Exploring the role of *Leishmania infantum* DYRK1 and Aurora kinases in the parasitic lifecycle for anti-leishmanial drug discovery", 11-9-14
4. **D. Smirlis** "*Leishmania* and leishmaniasis immunology, vaccine and drug discovery-therapy" Speaker: Recent approaches in anti-leishmanial drug discovery, 9-13 November 2016, Institut Pasteur, Tehran, Iran: International Workshop
5. **D. Smirlis** "Leishmaniasis: Current challenges in research and Public Health. 12th Panhellenic Conference on Public Health & Health Services". 19-21 March 2018, Athens

PUBLICATIONS

2001

1. Muangmoonchai R, **Smirlis D**, Wong SC, Edwards M, Phillips IR, Shephard EA. Xenobiotic induction of cytochrome P450 2B1 (CYP2B1) is mediated by the orphan nuclear receptor constitutive androstane receptor (CAR) and requires steroid co-activator 1 (SRC-1) and the transcription factor Sp1. *Biochem J.* 2001 Apr 1;355(Pt 1):71-8. doi: 10.1042/0264-6021:3550071
2. **Smirlis D**, Muangmoonchai R, Edwards M, Phillips IR, Shephard EA. Orphan receptor promiscuity in the induction of cytochromes p450 by xenobiotics. *J Biol Chem.* 2001 Apr 20;276(16):12822-6. doi: 10.1074/jbc.M005930200

2002

3. Muangmoonchai R, Wong SC, **Smirlis D**, Phillips IR, Shephard EA. Transfection of Liver in Vivo by Biolistic Particle Delivery: Its Use in the Investigation of Cytochrome P450 Gene Regulation. *Mol Biotechnol.* 2002 Feb; 20(2):145-51. doi: 10.1385/mb:20:2:145

2006

4. **Smirlis D**, Bisti SN, Xingi E, Konidou G, Thiakaki M, Soteriadou KP. *Leishmania* histone H1 overexpression delays parasite cell-cycle progression, parasite differentiation and reduces *Leishmania* infectivity *in vivo*. *Mol Microbiol.* 2006 Jun;60(6):1457-73. doi: 10.1111/j.1365-2958.2006.05205.x
5. Edwards M, Wong SC, Chotpadiwetkul R, **Smirlis D**, Phillips IR, Shephard EA Transfection of Primary Cultures of Rat Hepatocytes. *Methods Mol Biol.* 2006;320:273-282. doi: 10.1385/1-59259-998-2:273. (Book chapter)

2007

6. Georgopoulou K, **Smirlis D**, Sylvia Bisti, Xingi E, Skaltsounis L, Soteriadou K. In Vitro Activity of 10-deacetylbaccatin III Against *Leishmania* Donovanii Promastigotes and Intracellular Amastigotes. *Planta Med.* 2007 Aug; 73(10):1081-8. doi: 10.1055/s-2007-981579

2009

7. Xingi E, **Smirlis D**, Myrianthopoulos V, Magiatis P, Grant KM, Meijer L, Mikros E, Skaltsounis AL, Soteriadou K. 6-Br-5methylindirubin-3'oxime (5-Me-6-BIO) targeting the leishmanial glycogen synthase kinase-3 (GSK-3) short form affects cell-cycle progression and induces apoptosis-like death: exploitation of GSK-3 for treating leishmaniasis. *Int J Parasitol.* 2009 Oct;39(12):1289-303. doi: 10.1016/j.ijpara.2009.04.005
8. **Smirlis D***, Boleti H, Gaitanou M, Soto M, Soteriadou K. *Leishmania donovani* Ran-GTPase interacts at the nuclear rim with linker histone H1. *Biochem J.* 2009 Dec 10;424(3):367-74. doi: 10.1042/BJ20090576

2010

9. Boleti H, **Smirlis D**, Dalagiorgou G, Meurs EF, Christoforidis S, Mavromara P. ER targeting and retention of the HCV NS4B protein relies on the concerted action of multiple structural

features including its transmembrane domains. **Mol Membr Biol.** 2010 Jan;27(1):45-62. doi: 10.3109/09687680903426208

10. **Smirlis D***, Duszenko M, Ruiz AJ, Scoulica E, Bastien P, Fasel N, Soteriadou K. Targeting essential pathways in trypanosomatids gives insights into protozoan mechanisms of cell death. **Parasit Vectors.** 2010 Nov 17;3:107. doi: 10.1186/1756-3305-3-107 (**Review**)

2011

11. **Smirlis D***, Soteriadou, K. Trypanosomatid Apoptosis: 'Apoptosis' Without the Canonical Regulators. **Virulence** May-Jun 2011;2(3):253-6. doi: 10.4161/viru.2.3.16278. Epub 2011 May 1. DOI: 10.4161/viru.2.3.16278 (**invited addendum**)

2012

12. Soares MB, Silva CV, Bastos TM, Guimarães ET, Figueira CP, **Smirlis D**, Azevedo WF Jr. Anti-*Trypanosoma cruzi* activity of nicotinamide. **Acta Trop.** 2012 May;122(2):224-9. doi: 10.1016/j.actatropica.2012.01.001
13. Agallou M, **Smirlis D**, Soteriadou KP, Karagouni E. Vaccination with Leishmania histone H1-pulsed dendritic cells confers protection in murine visceral leishmaniasis. **Vaccine.** 2012 Jul 20;30(34):5086-93.

2013

14. Sacconay L, **Smirlis D**, Queiroz EF, Wolfender JL, Soares MB, Carrupt PA, Nurisso A. Structural insights of SIR2rp3 proteins as promising biotargets to fight against Chagas disease and leishmaniasis. **Mol Biosyst.** 2013 Sep;9(9):2223-30. doi: 10.1039/c3mb70180h
15. Vassilaki N, Kalliampakou KI, Kotta-Loizou I, Befani C, Liakos P, Simos G, Mentis AF, Kalliaropoulos A, Doumba PP, **Smirlis D**, Foka P, Bauhofer O, Poenisch M, Windisch MP, Lee ME, Koskinas J, Bartenschlager R, Mavromara P. Low oxygen tension enhances hepatitis C virus replication. **J Virol.** 2013 Mar;87(5):2935-48. doi: 10.1128/JVI.02534-12
16. Alexandratos A, Clos J, Samiotaki M, Efstathiou A, Panayotou G, Soteriadou K, **Smirlis D***. The loss of virulence of histone H1 overexpressing *Leishmania donovani* parasites is directly associated with a reduction of HSP83 rate of translation. **Mol Microbiol.** 2013 Jun;88(5):1015-31. doi: 10.1111/mmi.12240
17. Gouzelou E, Haralambous C, Antoniou M, Christodoulou V, Martinković F, Živičnjak T, **Smirlis D**, Pralong F, Dedet JP, Özbel Y, Toz SÖ, Presber W, Schönian G, Soteriadou K. Genetic diversity and structure in *Leishmania infantum* populations from southeastern Europe revealed by microsatellite analysis. **Parasit Vectors.** 2013 Dec 5;6:342. doi: 10.1186/1756-3305-6-342

2014

18. Efstathiou A, Gaboriaud-Kolar N, **Smirlis D**, Myrianthopoulos V, Vougianniopoulou K, Alexandratos A, Kritsanida M, Mikros E, Soteriadou K, Skaltsounis AL. An inhibitor-driven study for enhancing the selectivity of indirubin derivatives towards leishmanial Glycogen Synthase Kinase-3 over leishmanial cdc2-related protein kinase 3. **Parasit Vectors.** 2014 May 20;7:234. doi: 10.1186/1756-3305-7-234.
19. Stellas D, Souliotis VL, Bekyrou M, **Smirlis D**, Kirsch-Volders M, Degraffi F, Cundari E, Kyrtopoulos SA. Benzo[a]pyrene-induced cell cycle arrest in HepG2 cells is associated with delayed induction of mitotic instability. **Mutat Res.** 2014 Nov;769:59-68. doi: 10.1016/j.mrfmmm.2014.07.004
20. Becerra M, Sabrina Boutefnouchet, Cordoba O, Vitorino, Brehu L, Lamour I, Laimay F, Efstathiou A, **Smirlis D**, Michel S, Kritanida M, Flores MJ, Grougnet R. Antileishmanial activity of fucosterol recovered from *Lessonia vadosa* Searles (Lessoniaceae) by SFE, PSE and CPC. **Phytochem Lett** 2015 March, 11: 418-423. doi:10.1016/j.phytol.2014.12.019
21. Alexandratos A and **Smirlis D**. Protein Sample Preparation for Proteomic Analysis in *Leishmania donovani*. Bio-protocol. Vol 4, Iss 5, March 05, 2014. DOI: 10.21769/BioProtoc.1058. (**electronic journal**)
22. **Smirlis D***, Soares MB. Selection of molecular targets for drug development against trypanosomatids. **Subcell Biochem.** 2014;74:43-76. doi: 10.1007/978-94-007-7305-9_2. (**Book chapter**)

2015

23. Papadaki A, Politou AS, **Smirlis D**, Kotini MP, Kourou K, Papamarcaki T, Boleti H. The *Leishmania donovani* Histidine Acid Ecto-Phosphatase LdMAcP: Insight Into Its Structure and Function. **Biochem J.** 2015 May 1;467(3):473-86. doi: 10.1042/BJ20141371

2016

24. Azevedo L , Faqueti L., Kritsanida M., Efstathiou A., **Smirlis D.**, Franchi Jr GC, Genta-Jouve G., Michel S., Sandjo LP, Grougnet R, Biavatti MW. Three New Trixane Glycosides Obtained From the Leaves of *Jungia Sellowii* Less. Using Centrifugal Partition Chromatography. **Beilstein J Org Chem**. 2016 Apr 12;12:674-83. doi: 10.3762/bjoc.12.68

2017

25. Njock GBB, Grougnet R, Efstathiou A, **Smirlis D**, Genta-Jouve G, Michel S, Mbing JN, Kritsanida M. A Nitrile Glucoside and Biflavones from the Leaves of *Campylospermum excavatum* (Ochnaceae). **Chem Biodivers**. 2017 Nov;14(11). doi: 10.1002/cbdv.201700241
26. Kyriazis ID, **Smirlis D**, Papadaki A, Koutsoni O., Aligiannis N., Skaltsounis AL, Dotsika E. Leishmanicidal Activity of Oleuropein: *Leishmania donovani* Promastigote Cell Death through a Possibly ROS-Independent Mechanism. **J Pharmacogn Nat Prod** 2017, 3:2. DOI: 10.4172/2472-0992.1000141.

2018

27. Efstathiou A, Meira CS, Gaboriaud-Kolar N, Bastos TM, Rocha VPC, Vougianniopoulou K, Skaltsounis AL, **Smirlis D***, Soares* MBP. Indirubin derivatives are potent and selective anti-*Trypanosoma cruzi* agents **Virulence**. 2018; 9(1):1658-1668. doi:10.1080/21505594.2018.1532242.
28. Zoidis G, Tsoinias A, Tsatsaroni A, Taylor MC, Kelly JM, Efstathiou A, **Smirlis D**, Fytas G. Lipophilic conformationally constrained spiro carbocyclic 2,6-diketopiperazine-1-acetohydroxamic acid analogues as trypanocidal and leishmanicidal agents: An extended SAR study. **Chem Biol Drug Des**. 2018 Feb;91(2):408-421. doi: 10.1111/cbdd.13088
29. Bussotti G, Gouzouli E, Côrtes Boité M, Kherachi I, Harrat Z, Eddaikra N, Mottram JC, Antoniou M, Christodoulou V, Bali A, Guerfali FZ, Laouini D, Mukhtar M, Dumetz F, Dujardin JC, **Smirlis D**, Lechat P, Pescher P, El Hamouchi A, Lemrani M, Chicharro C, Llanes-Acevedo IP, Botana L, Cruz I, Moreno J, Jeddi F, Aoun K, Bouratbine A, Cupolillo E, Späth GF. *Leishmania* Genome Dynamics during Environmental Adaptation Reveal Strain-Specific Differences in Gene Copy Number Variation, Karyotype Instability, and Telomeric Amplification. **mBio**. 2018 Nov 6;9(6):e01399-18. doi: 10.1128/mBio.01399-18.

2019

30. Agallou M, Pantazi E, Tsiftsaki E, Toubanaki DK, Gaitanaki C, **Smirlis D**, Karagouni E. Induction of protective cellular immune responses against experimental visceral leishmaniasis mediated by dendritic cells pulsed with the N-terminal domain of *Leishmania infantum* elongation factor-2 and CpG oligodeoxynucleotides. **Mol Immunol**. 2018 Nov;103:7-20. doi: 10.1016/j.molimm.2018.08.004. 2019
31. Giraud E, Rouault E, Fiette L, Colle JH, **Smirlis D**, Melanitou E. Osteopontin in the host response to *Leishmania amazonensis*. **BMC Microbiol**. 2019 Feb 8;19(1):32. doi: 10.1186/s12866-019-1404-z.
32. Hombach-Barrigah A, Bartsch K, **Smirlis D**, Rosenqvist H, MacDonald A, Dingli F, Loew D, Späth GF, Rachidi N, Wiese M, Clos J. *Leishmania donovani* 90 kD Heat Shock Protein - Impact of Phosphosites on Parasite Fitness, Infectivity and Casein Kinase Affinity. **Sci Rep**. 2019 Mar 25;9(1):5074. doi: 10.1038/s41598-019-41640-0.
33. Efstathiou A, Gaboriaud-Kolar N, Myrianthopoulos V, Vougianniopoulou K, Subota I, Aicher S, Mikros E, Bastin P, Skaltsounis AL, Soteriadou K, **Smirlis D***. Indirubin Analogues Inhibit *Trypanosoma brucei* Glycogen Synthase Kinase 3 Short and *T. brucei* Growth. **Antimicrob Agents Chemother**. 2019 May 24;63(6):e02065-18. doi: 10.1128/AAC.02065-18. Print 2019 Jun.

2020

34. Martínez de Iturrate P, Sebastián-Pérez V, Náchter-Vázquez M, Tremper CS, **Smirlis D**, Martín J, Martínez A, Campillo NE, Rivas L, Gil C. Towards discovery of new leishmanicidal scaffolds able to inhibit *Leishmania* GSK-3. **J Enzyme Inhib Med Chem**. 2020 Dec;35(1):199-210. doi: 10.1080/14756366.2019.1693704.
35. Efstathiou A and **Smirlis D**. A Radioactive-free Kinase Inhibitor Discovery Assay Against the *Trypanosoma brucei* Glycogen Synthase Kinase-3 short (TbGSK-3s). **Bio-protocol**, January 20, 2020; 10(02): e3493. DOI:10.21769/BioProtoc.3493. (electronic journal)

36. Rocha VPC, Dacher M, Young SA, Kolokousi F, Efstathiou A, Späth GF, Soares MBP, **Smirlis D***. *Leishmania* dual-specificity tyrosine-regulated kinase 1 (DYRK1) is required for sustaining *Leishmania* stationary phase phenotype. **Mol Microbiol**. 2020 May;113(5):983-1002. doi: 10.1111/mmi.14464
37. **Smirlis D***, Dingli F, Pescher P, Prina E, Loew D, Rachidi N, Späth GF. SILAC-based quantitative proteomics reveals pleiotropic, phenotypic modulation in primary murine macrophages infected with the protozoan pathogen *Leishmania donovani*. **J Proteomics**. 2020 Feb 20;213:103617. doi: 10.1016/j.jprot.2019.103617.

2021

38. Efstathiou A, **Smirlis D**. *Leishmania* Protein Kinases: Important Regulators of the Parasite Life Cycle and Molecular Targets for Treating Leishmaniasis. **Microorganisms**. 2021 Mar 27;9(4):691. doi: 10.3390/microorganisms9040691. (**Review**)

2022

39. **Smirlis D**, Dingli F, Sabatet V, Roth A, Kippschild U, Loew D, Späth GF, Rachidi N. Identification of the Host Substratome of Leishmania-Secreted Casein Kinase 1 Using a SILAC-Based Quantitative Mass Spectrometry Assay. **Front. Cell Dev. Biol.**, 03 January 2022

METRICS (April 2022)

Scopus h-index: 16

Citation index Scopus: 830

Google Scholar h-index: 18

Citation index Google Scholar: 1118

REFEREED PROCEEDING OF INTERNATIONAL ABSTRACTS

1. Xingi E, **Smirlis D**, Bisti S, Myrianthopoulos V, Magiatis P, Meijer L, Mikros E, Skaltsounis A-L, Soteriadou K. Natural and synthetic indirubins as potent and selective inhibitors of the protozoan parasite *Leishmania donovani*. **Source: PLANTA MEDICA Volume: 73 Issue: 9 Pages: 942-943 Meeting Abstract: P382 Published: AUG 2007**
2. Vougoiannopoulou K, Gaboriaud-Kolar N, Efstathiou A, Soteriadou K, **Smirlis D**, Skaltsounis L. Identification of indirubin derivatives as anti-trypanosomal agents. Identification of indirubin derivatives as anti-trypanosomal agents. Conference: 62nd International Congress and Annual Meeting of the Society-of-Medicinal-Plant-and-Natural-Product-Research Location: Guimaraes, PORTUGAL Date: AUG 31-SEP 14. **Source: PLANTA MEDICA Meeting Abstract: 80 - P1L81 DOI: 10.1055/s-0034-1394738**
3. Gouzouli E, Tsoumani ME, Ntalas IV, Efstathiou A, **Smirlis D**, Goudevenos IA, Tselepis AD, Soteriadou K. The assessment of genetic polymorphisms and their potential association with aspirin resistance in a population of Greek patients with acute coronary syndrome. **Atherosclerosis**; July 2015, Volume 241, Issue 1, Page e133; EAS-0547
4. Tchoumtchoua J, Theocharis S, Halabalaki M, Efstathiou A, Gaboriaud-Kolar N., **Smirlis D**, Konstantinidou AE, Patsouris ES, Skaltsounis A-L. Toxicological study of the indirubin derivative 7BIO *Planta Med*. 2016 Dec;81(S 01):S1-S381. Epub 2016 Dec 14.

PRESENTATIONS AT INTERNATIONAL CONFERENCES

1. E.A. Shephard, S.C. Wong, M. Edwards, **D. Smirlis**, I. R. Phillips, R. L. Smith, M. H. Smith, I.R. Phillips. Mechanism of Phenobarbital action. 12th International Symposium on Microsomes and Drug Oxidations, Montpellier, France (1998) (Oral presentation)
2. **D. Smirlis**, R. Muangmoonchai, M. Edwards, I. R. Phillips, E.A. Shephard. Transcription factors that regulate xenobiotic induced *CYP2B1* gene expression. 13th International Symposium on Microsomes and Drug Oxidations, Stresa, Italy (2000) (Poster)
3. **D. Smirlis**, E. Xingi, S. Bisti, M. Thiakaki, K. Soteriadou. *Leishmania* histone H1 regulates parasite infectivity and cell-cycle progression (Oral presentation) Third World congress on Leishmaniasis (WorldLeish 3), Palermo-Terrasini, Sicily, Italy (2005)
4. C. Haralambous, **D. Smirlis**, K. Soteriadou. Exploitation of *histone H1* and *K26* gene polymorphisms for genotyping strains belonging to the *Leishmania donovani* complex Third World congress on Leishmaniasis (WorldLeish 3), Palermo-Terrasini, Sicily, Italy (2005) (Poster)

5. C. Haralambous, **D. Smirlis**, K. Soteriadou. Evidence for the presence of cis-regulating elements in the 3' UTRs of histone genes and of protein(s) interacting with this element Third World congress on Leishmaniosis (WorldLeish 3), Palermo-Terrasini, Sicily, Italy (2005) **(Poster, best poster award)**
6. **D. Smirlis**, K. Soteriadou Exploitation of *Leishmania* histone H1 as a novel target for antiparasitic drug development. Cost Action B22. Drug Discovery and development for parasitic diseases. Athens Greece (October 2006) (Oral presentation)
7. E. Xingi, **D. Smirlis**, S.Bisti, V. Myriantopoulos, P. Magiatis, L. Meijer, E. Mikros , A.L. Skaltsounis, K. Soteriadou. Natural and synthetic indirubins as potent and selective inhibitors of the protozoan parasite *Leishmania donovani*. Source: PLANTA MEDICA Volume: 73 Issue: 9 Pages: 942-943 Meeting Abstract: P382 Published: AUG 2007 (Poster)
8. E. Xingi, V. Myriantopoulos, **D. Smirlis**, S. Bisti, P. Magiatis, E. Mikros, L. Skaltsounis, K. Soteriadou. Indirubins as potent and selective inhibitors of the protozoan parasite *L. donovani*: *Leishmania* glycogen synthase kinase 3 a putative target of the 6- bromo-substituted indirubins. Cost Action B22. Drug Discovery and development for parasitic diseases. Athens Greece (October 2006) (Poster)
9. **D. Smirlis**, H. Boleti, M. Gaitanou, K. Soteriadou; The leishmanial Ran-GTPase system reveals an atypical Ran network. Understanding and controlling infectious diseases: an agenda for the 21st century. Institute Pasteur, Paris, France, 11-11-13 November 2008 (Oral presentation)
10. **D. Smirlis**, J. Clos, K. Soteriadou. *Leishmania* histone H1 modulates Hsp90 and elongation factor 2 protein levels and induces post-translational modifications in beta-tubulin. Understanding and controlling infectious diseases: an agenda for the 21st century. Institute Pasteur, Paris, France, 11-13 November 2008 (Poster)
11. E. Xingi, **D. Smirlis**, K-M. Grant , L. Meijer, A-L. Skaltsounis and K. Soteriadou. Exploitation of GSK-3beta for treating leishmaniasis, a trans-trypanosomatid drug target. Understanding and controlling infectious diseases: an agenda for the 21st century. Institute Pasteur, Paris, France, 11-11-13 November 2008 (Poster)
12. **D. Smirlis**, H. Boleti, M. Gaitanou, K. Soteriadou; The leishmanial Ran-GTPase system reveals an atypical Ran network. 4th World Congress on Leishmaniasis 2009, 3-7th February 2009, Lucknow, India (Oral presentation)
13. K. Soteriadou, C. Haralambous, E. Gouzelou, **P. Smirlis**, M-Z Alam, K. Kuhls, F. Paratlong, J-P. Dedet, M. Antoniou, G. Shonian. *Leishmania donovani* emergence in Europe: Cyprus evidence is an alarm call. 4th World Congress on Leishmaniasis 2009, 3-7th February 2009, Lucknow, India (Oral presentation)
14. C. Haralambous, **D. Smirlis**, M. Soto, K. Soteriadou. Molecular characterization of the stem-loop binding in *Leishmaniadonovani* and its putative role in histone modulation 4th World Congress on Leishmaniasis 2009, 3-7th February 2009, Lucknow, India (Poster)
15. K. Soteriadou, E. Xingi, **D. Smirlis**, K. M. Grant, L. Meijer, A.-L. Skaltsounis. Exploitation of GSK3-beta for treating Leishmaniasis, a trans-trypanosomatid drug target. 4th World Congress on Leishmaniasis 2009, 3-7th February 2009, Lucknow, India (Poster)
16. D. Ruiz, L. Ramirez, M. A. Pineda, C. Haralambous, **D. Smirlis**, K. Soteriadou, P. Bonay, M. Soto. Identification of cis-elements involved in the cell-cycle-dependent translation of *Leishmania* histone genes. 4th World Congress on Leishmaniasis 2009, 3-7th February 2009, Lucknow, India (Poster)
17. M. Agallou, **D. Smirlis**, K. Soteriadou, E. Karagouni. Protective role of nuclear histone H1 in experimental visceral Leishmaniasis. 4th World Congress on Leishmaniasis 2009, 3-7th February 2009, Lucknow, India (Poster)
18. M. Agallou, **D. Smirlis**, E. Dotsika, E. Karagouni. Dendritic cells exposed to 12-31 AA KMP-11 peptide and CpG ODNs confer protection against experimental visceral leishmaniasis.4th World Congress on Leishmaniasis 2009, 3-7th February 2009, Lucknow, India (Poster)
19. **D. Smirlis**, E.Xingi , V. Myriantopoulos , P. Magiatis , K.M. Grant, L. Meijer, E. Mikros ,A.L. Skaltsounis ,K. Soteriadou. Leishmanial glycogen synthase kinase-3 (GSK-3) short form affects cell-cycle progression and induces apoptosis-like death: exploitation of GSK-3 for treating leishmaniasisCOST BM0802 Meeting: Lausanne, Switzerland 11- 13 April 2010 (Oral presentation)
20. N. Vassilaki, K.I. Kalliampakou, I. Kotta-Loizou, **D. Smirlis**, R. Bartenschlager and P. Mavromara. Oxygen tension modulates hepatitis C virus proliferation, 4th European congress of virology, 7-11 April 2010
21. A. Efstathiou, **D. Smirlis**, A.-L.Skaltsounis, K. Soteriadou Indirubins a class of CDK/GSK-3 inhibitors, emerge as potential antiparasitics: Effect of indirubin substitutions on anti-trypanosomal and anti-leishmanial activities. COST BM0802 Meeting: Brussels, Belgium 27-29 March 2011 (Poster)
22. A. Alexandratos, J. Clos, M.Samiotaki, G.Panayotou, K. Soteriadou, **D. Smirlis**

The over-expression of *Leishmania* histone H1 renders *L. donovani* promastigotes more sensitive to apoptotic triggers: a proteomics screen for the identification of factors implicated in stress/drug-induced cell death. COST BM0802 Meeting: Brussels, Belgium 27-29 March 2011(Poster)

23. A. Efstathiou, **D. Smirlis**, A.-L.Skaltsounis, K. Soteriadou.The anti-parasitic effect of indirubin analogues on *L. donovani* and *T. brucei* parasites. COST BM0802 Meeting, Milan, 19-20 January 2012(Poster)

24. A. Alexandratos, J. Clos, M. Samiotaki, G. Panayotou, K. Soteriadou, **D. Smirlis**
The over-expression of *Leishmania* histone H1 renders *L. donovani* promastigotes more sensitive to apoptotic triggers: a proteomics screen implicates HSP90 in modulating sensitivity to stress/drug-induced cell death. COST BM0802 Meeting, Milan, 19-20 January, 2012 (Oral presentation)

25. A. Efstathiou, A.-L.Skaltsounis, K. Soteriadou, **D. Smirlis**; Evaluation of the *in vitro* antiparasitic activity of indirubins identifies a new class of anti-trypanosomal lead drug candidates. 8th Brazilian Symposium of Pharmacognosy and 11th International Symposium of the Brazilian Society of Pharmacognosy, Illheus-Bahia, Brazil: 18-22/4/2012) (Poster)

26. V. Pinto Costa Rocha, A. Efstathiou, M. B. P. Soares, **D. Smirlis**; Evaluation of a leishmanial DYRK kinase as a molecular target for the development of antileishmanial drugs. 5th World congress on Leishmaniasis, Porto de Galinhas, Pernambuco, Brazil 13 to 17 May 2013(Poster)

27. A. Efstathiou, L. Skaltsounis, K. Soteriadou, and **D. Smirlis**; Exploitation of parasitic kinases for the development of indirubin-based antitrypanosomatids, COST 4th Annual Meeting of Action CM0801 "New Drugs for Neglected Diseases" 19-21 September 2012, Kolymbari, Chania, Greece (Oral presentation)

28. I.D.Kyriazis, **D. Smirlis**, A. Papadaki, N. Aligiannis, P. Polychronopoulos, A.-L. Skaltsounis, E. Dotsika; Leishmanicidal activity assessment of olive tree extracts: Oleuropein a powerful antioxidant is able to promote *L. donovani* promastigote cell-death, COST 4th Annual Meeting of Action CM0801 "New Drugs for Neglected Diseases" Kolymbari, Chania, Greece (Poster)

29. V. Rocha, **D. Smirlis**, F.-R. Nonato, N. Aligiannis, K. Argyropoulou, I. Koloura, S. Amoah, M. Halabalaki, K. Soteriadou, A.-L. Skaltsounis, Milena B. P. Soares; Greek biodiversity as an important source of bioactive molecules to fight Leishmaniasis. 5th World congress on Leishmaniasis, Porto de Galinhas, Pernambuco, Brazil 13 to 17 May 2013 (Poster)

30. A. Efstathiou, **D. Smirlis**, V. Myriantopoulos, N. Gaboriaud-Kolar, K. Vougianniopoulou, E. Mikros, A.-L. Skaltsounis, K.Soteriadou; 3' bulky substitutions of 6-Br-indirubin-3'-oxime (6-BIO) primarily targeting CRK-3, shift specificity towards GSK-3. 5th World congress on Leishmaniasis, Porto de Galinhas, Pernambuco, Brazil 13 to 17 May 2013 (Poster)

31. **D. Smirlis**, Factors that modulate *Leishmania* infectivity and cell-cycle: Novel paradigms for antiparasitic drug discovery, Program of the Departmental days 2013, Parasitology and Mycology Department, Institut Pasteur, Paris, 18-19 June 2013 (Oral presentation)

32. A. Efstathiou, N.Gaboriaud-Kolar, V.Myriantopoulos, K.Vougianniopoulou, M.Kritsanida, E.Mikros, A.-L.Skaltsounis, K. Soteriadou, **D. Smirlis**. Indirubin analogues target trypanosomatid kinases: challenges and opportunities for treating trypanosomatid diseases. INSPiRE Workshop: Cell cycle and natural products, Athens, Greece, 8-9 May 2014 (Oral presentation)

33. K. Vougianniopoulou, N. Gaboriaud-Kolar, A. Efstathiou, K. Soteriadou, **D. Smirlis**, L. Skaltsounis. Identification of indirubin derivatives as anti-trypanosomal agents. Conference: 62nd International Congress and Annual Meeting of the Society-of-Medicinal-Plant-and-Natural-Product-Research Location: Guimaraes, PORTUGAL Date: AUG 31-SEP 04, 2014 Sponsor(s): Soc Med Plant & Nat Prod ResSource: PLANTA MEDICA Meeting Abstract: 80 - P1L81 DOI: 10.1055/s-0034-1394738 (2014)

34. **D. Smirlis**, M. Dacher, A. Efstathiou, G.F. Späth. Investigation of the biological role of *Leishmania infantum* dual-specificity tyrosine (Y) regulated kinase 1 (DYRK1) and evidence for its requirement in stress response, 4th conference on protein kinases of parasitic protozoa: targeting signaling pathways in parasitic protozoa & COST CM1307 meeting, Technion Institute of Research and Technology, Haifa, Israel, 22-25th March 2015

35. V. Pinto Costa Rocha, M. Dacher, F. Kolokousi, A. Efstathiou, G. F. Späth, M. B. P. Soares, **D. Smirlis**. Investigation of the biological role of *Leishmania infantum* dual-specificity tyrosine-regulated kinase (*Lin*DYRK1) and evidence for its participation in parasite-specific pathways": XXXI Annual Meeting of the Brazilian Society of Protozoology, 09 an 11 de Novembro de 2015 – Caxambu – MG – Brazil, **Award for best oral presentation**

36. **D. Smirlis**, P. Pescher, V. Hourdel, T. Douché, M. Matondo, N. Rachidi and G. F. Späth. Proteome and phosphoproteome profiling of *L. donovani* infected macrophages informs on new mechanisms of host immune subversion, Journées departmentals, 13-15 June, 2016 (Poster)

- 37.D. Smirlis** *In vitro* and *in vivo* antitrypanosomatid efficacy of GSK-3 inhibitors, PIV DRUG DEVELOPMENT Workshop, Institut Pasteur Paris, 28th April 2016 (Oral Presentation)
- 38.V. Pinto Costa Rocha, M. Dacher, F. Kolokousi, A. Efstathiou, G. F. Späth, M. B. P. Soares, D. Smirlis.** Genetic analysis of *Leishmania infantum* Aurora and DYRK1 kinases reveals their role in parasite survival and virulence respectively, TRYPANOSOMATID PARASITES FROM THE FIELD TO THE LAB, Institut Pasteur Paris, 26-27 May 2016 (Oral Presentation)
- 39.** Efstathiou A., Gaboriaud-Kolar N., Bouziotis D., Agallou M., Karagouni E., Skaltsounis A.-L., Soteriadou K. and **Smirlis D.** *In vitro* and *in vivo* anti-trypanosomatid efficacy of GSK-3 inhibitors, The new microbiology, EMBO Course, Spetses, Greece, 24-8/ 1-09-2016 (Poster)
- 40.** V. Pinto Costa Rocha, M. Dacher, F. Kolokousi, A. Efstathiou, G. F. Späth, M. B. P. Soares, **D. Smirlis.** *Leishmania infantum* DYRK1 in the development of infective promastigotes and in stage differentiation, BSP Autumn Symposium 2016, Durham, UK Microbial protein targets: towards understanding and intervention, 14-16 September 2016 (Oral presentation)
- 41.** Tchoumtchoua J.; Theocharis S.; Halabalaki M.; Efstathiou A; Gaboriaud-Kolar N; **Smirlis D**; Konstantinidou AE ; Patsouris ES; Skaltsounis AL. Toxicological study of the indirubin derivative 7BIO Conference: 9th Joint Meeting of AFERP, ASP, GA, JSP, PSE and SIF Location: Copenhagen, DENMARK Date: JUL 24-27, 2016 PLANTA MEDICA Volume: 82 Supplement: 1 Meeting Abstract: P952 Published: DEC 2016
- 42.** E. Gouzelou, P. Pescher, G. Bussotti², M. Antoniou, G. Späth, **D. Smirlis** Comparative analysis of genetically and phenotypically variable *Leishmania donovani* complex putative hybrids allows to explore their capacity for adaptive evolution 6th World Congress on Leishmaniasis, 16-20 May 2017 Toledo, Spain (Oral presentation)
- 43. D. Smirlis**, F. Dingli, D. Loew, G. F. Späth, N. Rachidi. Development of a new systems-wide screen to identify host substrates of the Leishmania excreted casein kinase isoform 1.2 6th World Congress on Leishmaniasis, 16-20 May 2017 Toledo, Spain (Oral presentation)
- 44. A. Efstathiou**, D. Bouziotis, N. Gaboriaud-Kolar, E. Karagouni, A.-L. Skaltsounis, K. Soteriadou, **D. Smirlis** GSK-3 inhibitors emerge in vitro and in vivo as new potential antitrypanosomatid therapy. 6th World Congress on Leishmaniasis, 16-20 May 2017 Toledo, Spain (Poster)
- 45.** V. Rocha, M. Dacher, A. Efstathiou, F. Kolokousi, G. F. Späth, M. B. P. Soares, **D. Smirlis** The *Leishmania* Dual Specificity Tyrosine Regulated Kinase 1: the positive side of a negative regulator 2 6th World Congress on Leishmaniasis, 16-20 May 2017 Toledo, Spain (Poster)
- 46.** Efstathiou, N. Gaboriaud-Kolar, C. Santana Meira, M. Agallou, M. B. P. Soares, E. Karagouni, A.-L. Skaltsounis, **D. Smirlis** Indirubins analogues as potent antikinoplastids via the inhibition of the parasitic Glycogen Synthase Kinase 3-short, Joint Retreat, Stapa Yupi 21-23 June 2018, Hellenic Pasteur Institute Athens, Greece (Poster)
- 47.** A. Efstathiou, N. Gaboriaud-Kolar, V. Myriantopoulos, E. Mikros, M. Agallou, D. Bouziotis, E. Karagouni, A.-L. Skaltsounis, **D. Smirlis** Indirubin analogues are promising compounds for the treatment of Leishmaniasis and Human African Trypanosomiasis, 30th International Symposium on the Chemistry of Natural Products, 25-29 November 2018, Athens, Greece (Poster)

PRESENTATIONS AT NATIONAL CONFERENCES

1. A. Tartas, **D. Smirlis**, N. Gounalaki, D. Tzamaras, M. Pelecanou, M. Vlassi. Circular Dichroism Structures Studies on the Interaction Domains of the Yeast Transcriptional Repressors SSN6 and Tup1. Hellenic Society of Biochemistry and Molecular Biology (53rd meeting), Chios, Greece (2001)
2. **D. Smirlis**, Seferi, M., Papamichos-Chronakis, M., Ladopoulou, A., Pelecanou, M., Tzamaras, D. & M. Vlassi (2001) Cloning, expression, and purification of the 108 N-terminal residues of the yeast transcriptional repressor Tup1. 23rd Panhellenic Conference of Hellenic Association for Biological Sciences, May 24-27, 2001, Chios Island. 50
3. **D. Smirlis**, M. Thiakaki, G. Konidou, K. Soteriadou. *Leishmania* 18 KD Nuclear Protein Regulates *Leishmania* Infectivity *in vivo*. Hellenic Society of Biochemistry and Molecular Biology (55th meeting) Athens Greece (2003).
4. **D. Smirlis**, H. Boleti, M. Gaitanou, K. Soteriadou. Identification, cloning, and characterization of the small Ras-related GTP-binding protein RAN, in the protozoan parasite *Leishmania* (59th Panhellenic Congress of Biochemistry and Molecular Biology, Athens (7-9 December 2007)

5. **D. Smirlis**, E. Xingi, P. Bastin, K.Soteriadou. GSK-3, a drug target for treating Leishmaniasis and Human African Trypanosomiasis, is involved in crucial life-cycle pathways in *Trypanosomatidae*. (60th Panhellenic Congress of Biochemistry and Molecular Biology, Athens (2009)
6. C. Haralambous, **D. Smirlis**, D. Ruiz, M. Soto, K. Soteriadou Identification and molecular characterization of cis- and trans-acting elements regulating the cell-cycle dependent expression of *Leishmania* histones. (60th Panhellenic Congress of Biochemistry and Molecular Biology, Athens (2009)
7. M. Kotini, A. Papadaki, **D. Smirlis**, K. Soteriadou, H. Boleti. Generation of transgenic *Leishmania donovani* expressing Red Fluorescent Protein: a tool for *in vivo* imaging of the parasite-host interaction (60th Panhellenic Congress of Biochemistry and Molecular Biology, Athens (2009)
8. A. Papadaki, M. Kotini, **D. Smirlis**, J. Pizarro-Cerda, K. Soteriadou, H. Boleti. Phosphoinositide involvement in *Leishmania donovani* phagocytosis by macrophages. (60th Panhellenic Congress of Biochemistry and Molecular Biology, Athens (2009).
9. A. Efstathiou, A. Alexandratos, **D. Smirlis**, K. Soteriadou. Anti-leishmanial and anti-trypanosomal action of inhibitors targeting the parasitic GSK3, 5th National Conference on Clinical Microbiology and Nosocomial Infections 10-12 February 2011 Athens
10. A. Alexandratos, A. Efstathiou, K.Soteriadou, **D.Smirlis***. The reduced virulence of *Leishmania donovani* parasites that overexpress Leishmania Histone H1 is associated with the reduced expression of HSP90 5ο Εθνικό συνέδριο κλινικής Μικροβιολογίας και νοσοκομειακών λοιμώξεων. 10-12 Φεβρουαρίου 2011 Αθήνα, 5th National Conference on Clinical Microbiology and Nosocomial Infections 10-12 February 2011 Athens
11. **D. Smirlis***, F. Dingli, P. Pescher, E. Prina, D. Loew, N. Rachidi, G. F. Späth* Proteomic patterns of bona fide primary macrophages infected *ex vivo* with *Leishmania donovani* provide specific insights into the interplay between host and parasite. EEBMB January- June 2021. Online conference (Oral presentation)

PARTICIPATION IN RESEARCH PROJECTS/ GRANTS

2009-2011 2014-2018	Appointed Greek MC substitute member a) BM0802 Action - Life or death of protozoan parasites; b) CM1307 “Targeted chemotherapy towards diseases caused by endoparasites”
2011-2012	Foundation for Education and European Culture (IPEP) : “Evaluation of the anti-leishmanial action of new indirubin analogues”(2011-2012) (Main Recipient of Grant) (3000 €)
2011-2014	NATIONAL ACTION COOPERATION GSRT : Exploring new markers for diagnosis of resistance to antiplatelet drugs in patients with cardiovascular disease. Budget:150000€ (member)
2013-2015	ACIP 2013 – International Pasteur Network (IPIN) : “Evaluation of <i>Leishmania</i> DYRK family of kinases as molecular targets for the development of anti-leishmanial drugs” (Hellenic Pasteur Institute, IP Paris, IP Montevideo, FIOCRUZ) (Coordinator) Project Budget : 59 000 €
2014-2015	LeiShield : A new collaborative action to determine prevalence, anticipate emergence and assess urbanization of CL and VL in LeishRIIP partner countries (PI)- (Budget 7500€)
2011 –2015	FP7-PEOPLE-2010-IRSES : Exploring Chemical Biodiversity with Innovative Approaches for Fighting Chagas and Leishmaniasis. PIRCES-GA-2010-269301 (Co-WP leader with Dr K. Soteriadou) Budget: 48 300 €
2012-2015	GSRT KRIPIS :Infectious and neurodegenerative diseases of the 21st Century: From the study of basic mechanisms to translational research and development of cutting-edge technologies aiming towards prevention, diagnosis and treatment (WP leader), Budget: 60241€ (WP Leader)
10-2017/ 09-2019	GSRT KRIPIS : Infectious, autoimmune and neurodegenerative diseases: Study of Pathogenic Mechanisms and development of diagnostic, prognostic and therapeutic approaches” Budget: 21000€ (WP leader)
2016-2017	IKY-SIEMENS: Υποτροφία μεταδιδακτορικού συνεργάτη Excellence- SIEMENS (2016-2017) supported by the Hellenic State Scholarships Foundation IKY-SIEMENS [grant no: 2016-017-0173-10398], με τίτλο “Investigation of the antiparasitic activity of drugs for the discovery of new treatments against parasitic diseases whose aetiological agents are parasites of the family of trypanosomatids” (Budget: 20 000€), 30th June 2016- 31th August 2017)
11/2021-8/2023	Calmette Yersin Doctoral Fellowship (Institute Pasteur Network):

	Phospho-signaling at the host-pathogen interface: the role of DYRKs and other kinases in <i>Leishmania</i> infections. Recipient: Daniel Navarro Carrasco
--	--

RECENTLY SUBMITTED PROJECTS THAT WERE SHORTLISTED BUT NOT FUNDED

- **June 1, 2020:** Targeting of the macrophage lysosomal system as a novel host-directed therapy to treat leishmaniasis **2nd Call for H.F.R.I. Research Projects to support Faculty Members and Researchers**; Budget requested: 199984 euros: **Passed into the second phase of evaluation (PI- Researcher in charge)**
- **2021:** Macrophage nuclear receptors as novel targets for host-directed therapies against leishmaniasis. The budget requested: 193 000 euros. Role: Coordinator. **Was in the supplementary list of approved projects.** Resubmission was requested if it was not positively evaluated

SUBMITTED PROJECTS (AWAITING EVALUATION)

- **4th February 2022:** Exploiting the macrophage nuclear receptors, as novel drug targets for host-directed therapies against visceral leishmaniasis, PTR, Institute Pasteur Network. Budget Requested:
- **1st February 2022:** NOVEL VACCINES FOR LEISHMANIASIS BASED ON AN INNOVATIVE RNA VACCINE TECHNOLOGY LeishRNAvac HORIZON-HLTH-2022-DISEASE-06-03-two-stage. Type of action: HORIZON-RIA proposal EC. Budget requested: 5500000.00 euro. Role: Member